Literature DB >> 19844660

TNF-blockade in patients with advanced hormone refractory prostate cancer.

Luis A Diaz1, Wells Messersmith, Lori Sokoll, Vicki Sinibaldi, Sandy Moore, Michael Carducci, Mario Eisenberger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19844660      PMCID： PMC3272825          DOI： 10.1007/s10637-009-9346-1

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  12 in total

Review 1.  Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.

Authors:  I Bernard Weinstein; Andrew K Joe
Journal:  Nat Clin Pract Oncol       Date:  2006-08

2.  Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.

Authors:  S F Shariat; B Andrews; M W Kattan; J Kim; T M Wheeler; K M Slawin
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

3.  Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.

Authors:  Hannes Steiner; Ilaria T Cavarretta; Patrizia L Moser; Andreas P Berger; Jasmin Bektic; Hermann Dietrich; Mohamed H Zaki; Marian Nakada; Alfred Hobisch; Jeffrey A Nemeth; Zoran Culig
Journal:  Prostate       Date:  2006-12-01       Impact factor: 4.104

4.  Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.

Authors:  P C Smith; E T Keller
Journal:  Prostate       Date:  2001-06-15       Impact factor: 4.104

5.  Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.

Authors:  M Okamoto; C Lee; R Oyasu
Journal:  Cancer Res       Date:  1997-01-01       Impact factor: 12.701

6.  Interleukin-6: a candidate mediator of human prostate cancer morbidity.

Authors:  D A Twillie; M A Eisenberger; M A Carducci; W S Hseih; W Y Kim; J W Simons
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

7.  The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

Authors:  Daniel J George; Susan Halabi; Timothy F Shepard; Ben Sanford; Nicholas J Vogelzang; Eric J Small; Philip W Kantoff
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

8.  The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1.

Authors:  I T Cavarretta; H Neuwirt; G Untergasser; P L Moser; M H Zaki; H Steiner; H Rumpold; D Fuchs; A Hobisch; J A Nemeth; Z Culig
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

9.  Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

Authors:  Kamilla Malinowska; Hannes Neuwirt; Ilaria T Cavarretta; Jasmin Bektic; Hannes Steiner; Hermann Dietrich; Patrizia L Moser; Dietmar Fuchs; Alfred Hobisch; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2008-11-14       Impact factor: 5.678

10.  Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.

Authors:  Kathleen M Woods Ignatoski; Judah Friedman; June Escara-Wilke; Xiaohua Zhang; Stephanie Daignault; Rodney L Dunn; David C Smith; Evan T Keller
Journal:  J Interferon Cytokine Res       Date:  2009-02       Impact factor: 2.607
View more
  3 in total

Review 1.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

Review 2.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

3.  Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology.

Authors:  Brian W C Tse; Kieran F Scott; Pamela J Russell
Journal:  Prostate Cancer       Date:  2012-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.